COLORADO SPRINGS, Colo.,
Aug. 25, 2014 /PRNewswire/
-- Cannabis Science, Inc. (OTC-QB: CBIS), a U.S. company
specializing in cannabis formulation-based drug development and
related consulting, is pleased to announce that it is in the final
stages of negotiations for the acquisition of a company that has
applied for a "Marihuana for Medical Purposes" (Canada) license with Health Canada. The
application includes a site located in British Columbia, Canada with a highly
experienced and professional team. The target company currently
produces cannabis under the "Marihuana Medical Access Regulations"
(Canada).
The target company's facility is approximately 10,000 square
feet and is already providing medical cannabis to patients under
Canada's "Marihuana Medical Access
Regulations". Upon receiving the final license under the new
Canadian regulations, the Company intends to utilize its team
medical and industry experts both to begin research and development
into medicine derived from cannabis and to commercially sell
medical cannabis produced at the facility in British Columbia, Canada.
The Company is also in talks with medical doctors in
Canada in order to collaborate on
research and trials involving cannabinoids. Dorothy H. Bray, Ph.D., Director, President and
CEO of Cannabis Science commented, "The new regulatory regime in
Canada allows medical cannabis
producers and clinical researchers to collaborate and undertake
research for the benefit of patients in manner previously
unavailable in Canada."
The subject of this news release are unrelated and in addition
to the previously announced joint-venture in Canada for a medical cannabis at issue in a
Company news release dated August 7,
2014.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique
understanding of metabolic processes to provide novel treatment
approaches to a number of illnesses for which current treatments
and understanding remain unsatisfactory. The Company works with
leading experts in drug development, medicinal characterization,
and clinical research to develop, produce, and commercialize novel
therapeutic approaches for the treatment for illnesses caused by
infections as well as for age-related illness. Our initial focus is
on skin cancers and neurological conditions.
Forward Looking Statements
This Press Release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, that are not
historical facts, and involve risks and uncertainties that could
cause actual results to differ materially from those expected and
projected. A statement containing words such as "anticipate,"
"seek," intend," "believe," "estimate," "expect," "project,"
"plan," or similar phrases may be deemed "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements relate to
future events or future performance, but reflect CBIS management's
current beliefs, based on information currently available. Some or
all of the events or results anticipated by these forward-looking
statements may not occur. A number of factors could cause actual
events, performance or results to differ materially from the
events, performance and results discussed in the forward-looking
statements.
Factors that could cause or contribute to such differences
include the future U.S. and global economies, the impact of
competition, and the Company's reliance on existing regulations
regarding the use and development of cannabis-based drugs. Cannabis
Science, Inc., does not undertake any duty nor does it intend to
update the results of these forward-looking statements, whether as
a result of new information, future events or otherwise.
Cannabis Science, Inc.
Dr. Dorothy Bray, CEO &
Director
www.cannabisscience.com
dorothy.bray@cannabisscience.com
info@cannabisscience.com
Tel: 1.888.777.0658
Investment Inquiries
Robert Kane, CFO & Director
robert.kane@cannabisscience.com
Tel: 1.561.420.4824
Cannabis Science, Inc.
Raymond C. Dabney, Management
Consultant, Co-Founder
raymond@cannabisscience.com
Tel: 1.310.650.3788
SOURCE Cannabis Science, Inc.